368 related articles for article (PubMed ID: 33314633)
1. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
[TBL] [Abstract][Full Text] [Related]
2. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH
Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129
[TBL] [Abstract][Full Text] [Related]
3. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer landscape of
Huang RSP; Murugesan K; Montesion M; Pavlick DC; Mata DA; Hiemenz MC; Decker B; Frampton G; Albacker LA; Ross JS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972391
[TBL] [Abstract][Full Text] [Related]
5. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
Jang BS; Han W; Kim IA
Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Huang RSP; Li X; Haberberger J; Sokol E; Severson E; Duncan DL; Hemmerich A; Edgerly C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Hiemenz M; Xiao J; McEwan D; Holmes O; Danziger N; Erlich R; Frampton G; Cohen MB; McGregor K; Reddy P; Cardeiro D; Anhorn R; Venstrom J; Alexander B; Brown C; Pusztai L; Ross JS; Ramkissoon SH
Oncologist; 2020 Nov; 25(11):943-953. PubMed ID: 32869930
[TBL] [Abstract][Full Text] [Related]
7. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
[TBL] [Abstract][Full Text] [Related]
8. Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
Contos G; Baca Y; Xiu J; Brown J; Holloway R; Korn WM; Herzog TJ; Jones N; Winer I
Gynecol Oncol; 2021 Nov; 163(2):312-319. PubMed ID: 34563366
[TBL] [Abstract][Full Text] [Related]
9. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
[TBL] [Abstract][Full Text] [Related]
12. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Huang RSP; Haberberger J; McGregor K; Mata DA; Decker B; Hiemenz MC; Lechpammer M; Danziger N; Schiavone K; Creeden J; Graf RP; Strowd R; Lesser GJ; Razis ED; Bartsch R; Giannoudis A; Bhogal T; Lin NU; Pusztai L; Ross JS; Palmieri C; Ramkissoon SH
Oncologist; 2021 Oct; 26(10):835-844. PubMed ID: 34105210
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
Gatalica Z; Xiu J; Swensen J; Vranic S
Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
[TBL] [Abstract][Full Text] [Related]
15. Tumor Mutational Burden and
Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
[TBL] [Abstract][Full Text] [Related]
17. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
[TBL] [Abstract][Full Text] [Related]
18. Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (
Bou Zerdan M; Ashok Kumar P; Haroun E; Srivastava N; Ross J; Sivapiragasam A
Oncotarget; 2023 Mar; 14():178-187. PubMed ID: 36913304
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]